BackNabriva Therapeutics Plc Overview

Nabriva Therapeutics Plc Net Tangible Assets

Latest net tangible assets for NBRV: $-4.4M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$-4.36M
109.76% YoYΔ $-48.98M vs prior year quarter

Peer trimmed avg / median

Loading

Nabriva Therapeutics Plc Net Tangible Assets History

Loading

Nabriva Therapeutics Plc vs. peers: Net Tangible Assets Comparison

Loading

Nabriva Therapeutics Plc Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Nabriva Therapeutics Plc (NBRV) FAQ

Nabriva Therapeutics Plc's net tangible assets stands at $-4.4M as of March 2023. That compares with $45M in the prior-year period — down 109.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Nabriva Therapeutics Plc reported $-4.4M in net tangible assets versus $45M a year earlier — a 109.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $45M in the prior-year period — down 109.8% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Nabriva Therapeutics Plc's net tangible assets evolved across reporting periods, while the comparison chart places NBRV next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. Nabriva Therapeutics Plc's reading of $-4.4M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.